Novartis Sues Noven To Block Generic Dementia Patch
Law360, New York (April 3, 2013, 6:49 PM EDT) -- Novartis AG slapped Hisamitsu Pharmaceutical Co. Inc. and subsidiary Noven Pharmaceuticals Inc. with a lawsuit in Delaware on Wednesday, claiming Noven infringed two patents by seeking U.S. regulatory approval for a generic version of Novartis' dementia-treating Exelon patch.
Novartis and patent co-owner LTS Lohmann Therapie-Systeme AG's complaint against Japan-based Hisamitsu and two Noven units asked the court for injunctive relief as well as an order declaring that U.S. Food and Drug Administration approval of Noven's proposed rivastigmine transdermal system can't come before the plaintiffs' rights under the two patents-in-suit expire.
Novartis Pharmaceuticals Corp., also a plaintiff, holds an approved new drug...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!